These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33822015)

  • 1. Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America.
    Forrat R; Dayan GH; DiazGranados CA; Bonaparte M; Laot T; Capeding MR; Sanchez L; Coronel DL; Reynales H; Chansinghakul D; Hadinegoro SRS; Perroud AP; Frago C; Zambrano B; Machabert T; Wu Y; Luedtke A; Price B; Vigne C; Haney O; Savarino SJ; Bouckenooghe A; Noriega F
    Clin Infect Dis; 2021 Sep; 73(6):1003-1012. PubMed ID: 33822015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus.
    Dayan GH; Langevin E; Forrat R; Zambrano B; Noriega F; Frago C; Bouckenooghe A; Machabert T; Savarino S; DiazGranados CA
    Vaccine; 2020 Sep; 38(41):6472-6477. PubMed ID: 32773243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus.
    Dayan GH; Langevin E; Gilbert PB; Wu Y; Moodie Z; Forrat R; Price B; Frago C; Bouckenooghe A; Cortes M; Noriega F; DiazGranados CA
    Vaccine; 2020 Apr; 38(19):3531-3536. PubMed ID: 32204943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia.
    Reynales H; Carrasquilla G; Zambrano B; Cortés S M; Machabert T; Jing J; Pallardy S; Haney O; Faccini M; Quintero J; Noriega F
    Pediatr Infect Dis J; 2020 Apr; 39(4):e30-e36. PubMed ID: 32040014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy.
    Sridhar S; Luedtke A; Langevin E; Zhu M; Bonaparte M; Machabert T; Savarino S; Zambrano B; Moureau A; Khromava A; Moodie Z; Westling T; Mascareñas C; Frago C; Cortés M; Chansinghakul D; Noriega F; Bouckenooghe A; Chen J; Ng SP; Gilbert PB; Gurunathan S; DiazGranados CA
    N Engl J Med; 2018 Jul; 379(4):327-340. PubMed ID: 29897841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals.
    DiazGranados CA; Langevin E; Bonaparte M; Sridhar S; Machabert T; Dayan G; Forrat R; Savarino S
    Clin Infect Dis; 2021 May; 72(10):1730-1737. PubMed ID: 32198515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
    Coronel-MartÍnez DL; Park J; López-Medina E; Capeding MR; Cadena Bonfanti AA; Montalbán MC; Ramírez I; Gonzales MLA; DiazGranados CA; Zambrano B; Dayan G; Savarino S; Chen Z; Wang H; Sun S; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
    Lancet Infect Dis; 2021 Apr; 21(4):517-528. PubMed ID: 33212067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with a new dengue rapid diagnostic test: a retrospective analysis of phase 3 efficacy trials.
    Savarino SJ; Bonaparte M; Wang H; Dayan GH; Forrat R; Zhu M; Hodge S; Ataman-Önal Y; DiazGranados CA
    Lancet Microbe; 2022 Jun; 3(6):e427-e434. PubMed ID: 35659904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials.
    DiazGranados CA; Bonaparte M; Wang H; Zhu M; Lustig Y; Schwartz E; Forrat R; Dayan GH; Hodge S; Ataman-Önal Y; Savarino SJ
    Lancet Infect Dis; 2021 Apr; 21(4):529-536. PubMed ID: 33212068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of a tetravalent dengue vaccine in children in Latin America.
    Villar L; Dayan GH; Arredondo-García JL; Rivera DM; Cunha R; Deseda C; Reynales H; Costa MS; Morales-Ramírez JO; Carrasquilla G; Rey LC; Dietze R; Luz K; Rivas E; Miranda Montoya MC; Cortés Supelano M; Zambrano B; Langevin E; Boaz M; Tornieporth N; Saville M; Noriega F;
    N Engl J Med; 2015 Jan; 372(2):113-23. PubMed ID: 25365753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease.
    Scott LJ
    Drugs; 2016 Sep; 76(13):1301-1312. PubMed ID: 27506852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children/adolescents to adults in highly endemic countries.
    Huang Y; Moodie Z; Juraska M; Fong Y; Carpp LN; Chambonneau L; Coronel DL; Dayan GH; DiazGranados CA; Gilbert PB
    Trans R Soc Trop Med Hyg; 2021 Jul; 115(7):750-763. PubMed ID: 33369671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Response Persistence and Safety of a Booster Dose of the Tetravalent Dengue Vaccine in Adolescents and Adults Who Previously Completed the 3-dose Schedule 4-5 Years Earlier in Latin America: A Randomized Placebo-controlled Trial.
    Coronel D; García-Rivera EJ; Rivera DM; Arredondo-García JL; Dietze R; Perroud AP; Cortés M; Bonaparte M; Wang H; Pagnon A; Jantet-Blaudez F; Peñalosa LAR; Dayan G; Zambrano B; DiazGranados CA; Noriega F
    Pediatr Infect Dis J; 2020 Oct; 39(10):961-968. PubMed ID: 32932330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America.
    Moodie Z; Juraska M; Huang Y; Zhuang Y; Fong Y; Carpp LN; Self SG; Chambonneau L; Small R; Jackson N; Noriega F; Gilbert PB
    J Infect Dis; 2018 Feb; 217(5):742-753. PubMed ID: 29194547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America.
    Arredondo-García JL; Hadinegoro SR; Reynales H; Chua MN; Rivera Medina DM; Chotpitayasunondh T; Tran NH; Deseda CC; Wirawan DN; Cortés Supelano M; Frago C; Langevin E; Coronel D; Laot T; Perroud AP; Sanchez L; Bonaparte M; Limkittikul K; Chansinghakul D; Gailhardou S; Noriega F; Wartel TA; Bouckenooghe A; Zambrano B;
    Clin Microbiol Infect; 2018 Jul; 24(7):755-763. PubMed ID: 29408333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials.
    Gailhardou S; Skipetrova A; Dayan GH; Jezorwski J; Saville M; Van der Vliet D; Wartel TA
    PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004821. PubMed ID: 27414655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials.
    Plennevaux E; Moureau A; Arredondo-García JL; Villar L; Pitisuttithum P; Tran NH; Bonaparte M; Chansinghakul D; Coronel DL; L'Azou M; Ochiai RL; Toh ML; Noriega F; Bouckenooghe A
    Clin Infect Dis; 2018 Apr; 66(8):1164-1172. PubMed ID: 29300876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy Trials.
    Huang Y; Williamson BD; Moodie Z; Carpp LN; Chambonneau L; DiazGranados CA; Gilbert PB
    J Infect Dis; 2022 Jan; 225(2):332-340. PubMed ID: 34174082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America.
    Villar LÁ; Rivera-Medina DM; Arredondo-García JL; Boaz M; Starr-Spires L; Thakur M; Zambrano B; Miranda MC; Rivas E; Dayan GH
    Pediatr Infect Dis J; 2013 Oct; 32(10):1102-9. PubMed ID: 24067553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin America.
    Olivera-Botello G; Coudeville L; Fanouillere K; Guy B; Chambonneau L; Noriega F; Jackson N;
    J Infect Dis; 2016 Oct; 214(7):994-1000. PubMed ID: 27418050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.